Statement of Principles concerning myocarditis (Reasonable Hypothesis) (No. 17 of 2024)
1Statement of Principles concerning myocarditis (Reasonable Hypothesis) (No. 17 of 2024)
Start here
Get a plain-English read of 1
Turn the raw legal text into a practical explanation grounded in Statement of Principles concerning myocarditis (Reasonable Hypothesis) (No. 17 of 2024).
6 Kind of injury, disease or death to which this Statement of Principles relates
7 Basis for determining the factors
8 Factors that must exist
9 Relationship to service
10 Factors referring to an injury or disease covered by another Statement of Principles
Schedule 1 - Dictionary
1 Definitions
1 Name
This is the Statement of Principles concerning myocarditis (Reasonable Hypothesis) (No. 17 of 2024).
2 Commencement
This instrument commences on 26 March 2024.
3 Authority
This instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.
4 Application
This instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.
5 Definitions
The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.
6 Kind of injury, disease or death to which this Statement of Principles relates
(1) This Statement of Principles is about myocarditis and death from myocarditis.
Meaning of myocarditis
(2) For the purposes of this Statement of Principles, myocarditis:
(a) means an inflammation of the heart muscle (myocardium); and
(b) excludes inflammation associated with coronary artery disease.
(3) While myocarditis attracts ICD‑10‑AM codes I40, I41, I01.2, I09.0, I51.4, in applying this Statement of Principles the meaning of myocarditis is that given in subsection (2).
(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Death from myocarditis
(5) For the purposes of this Statement of Principles, myocarditis, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's myocarditis.
Note: terminal event is defined in the Schedule 1 – Dictionary.
7 Basis for determining the factors
The Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that myocarditis and death from myocarditis can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.
Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.
8 Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting myocarditis or death from myocarditis with the circumstances of a person's relevant service:
(1) undergoing a course of radiotherapy for cancer, where the heart was in the field of radiation, before clinical onset or clinical worsening;
(2) having a myocardial infection at the time of clinical onset or clinical worsening;
(3) having a systemic viral infection within the 4 weeks before clinical onset or clinical worsening;
(4) being infected with human immunodeficiency virus before clinical onset or clinical worsening;
(5) having tuberculosis before clinical onset or clinical worsening;
(6) having acute rheumatic fever at the time of clinical onset or clinical worsening;
(7) having one of the following vasculitides:
(a) Behcet disease;
(b) eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome);
(c) giant cell (temporal) arteritis;
(d) granulomatosis with polyangiitis (Wegener granulomatosis);
(e) Kawasaki disease;
(f) polyarteritis nodosa; or
(g) Takayasu arteritis;
at the time of clinical onset or clinical worsening;
(8) having one of the following systemic inflammatory diseases:
(a) antiphospholipid syndrome;
(b) coeliac disease;
(c) dermatomyositis;
(d) Graves disease;
(e) Hashimoto disease;
(f) IgG4-related disease;
(g) inflammatory bowel disease;
(h) mixed connective tissue disease;
(i) polymyositis;
(j) psoriatic arthritis;
(k) rheumatoid arthritis;
(l) scleroderma (progressive systemic sclerosis);
(m) Sjögren syndrome; or
(n) systemic lupus erythematosus;
at the time of clinical onset or clinical worsening;
(9) having acute pancreatitis at the time of clinical onset or clinical worsening;
(10) having myasthenia gravis at the time of or before clinical onset or clinical worsening;
(11) having cardiac graft acute cellular rejection at the time of clinical onset;
(12) having a haematopoietic stem cell transplant within the 4 years before clinical onset or clinical worsening;
(13) having a phaeochromocytoma or thymoma at the time of clinical onset or clinical worsening;
(14) being treated with one of the following medications within the 3 months before clinical onset or clinical worsening:
(a) alkylating agents including cyclophosphamide;
(b) anthracyclines including doxorubicin, daunorubicin, idarubicin, epirubicin and mitoxantrone;
(c) antibiotics including penicillin, cephalosporins, tetracyclines, sulphonamides, isoniazid, and streptomycin;
(d) carbamazepine;
(e) diuretics including furosemide and thiazides;
(f) dobutamine;
(g) dopamine;
(h) fluoropyrimidines including 5-fluorouracil and capecitabine;
(i) immune checkpoint inhibitors including atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatilimab, retifanlimab, and tremelimumab;
(j) mesalazine (5-aminosalicylic acid);
(k) methyl dopa;
(l) paracetamol poisoning;
(m) phenytoin;
(n) quetiapine;
(o) tricyclic antidepressants;
(p) tumour necrosis factor alpha antagonists including infliximab;
(15) being treated with clozapine within the 2 years before clinical onset or clinical worsening;
(16) taking a medication for at least 7 days which is associated in the individual with the clinical onset of myocarditis during medication therapy; and which is associated with:
(a) an increase in the symptoms and signs of myocarditis during drug therapy; and
(b) cessation of the symptoms and signs of myocarditis within weeks of discontinuing drug therapy;
(17) having a COVID-19 vaccine within the 4 weeks before clinical onset or clinical worsening;
(18) having smallpox vaccine within the 4 weeks before clinical onset or clinical worsening;
(19) using cocaine within the 3 months before clinical onset or clinical worsening;
(20) being envenomated by a scorpion, wasp, hornet, bee, spider of the Latrodectus spp. (including red back spider, katipo spider and black widow spider) or funnel web spider within the 24 hours before clinical onset;
(21) being envenomated by a brown recluse spider (Loxosceles reclusa) within the one week before clinical onset;
(22) ingesting wild mushrooms or toadstools within the 7 days before clinical onset;
(23) having organophosphate poisoning or paraphenylene diamine poisoning at the time of clinical onset or clinical worsening;
(24) having chronic lead poisoning at the time of clinical onset or clinical worsening;
(25) having an alcohol use disorder at the time of clinical onset or clinical worsening;
(26) inability to obtain appropriate clinical management for myocarditis before clinical worsening.
9 Relationship to service
(1) The existence in a person of any factor referred to in section 8, must be related to the relevant service rendered by the person.
(2) The clinical worsening aspects of factors set out in subsection 8 apply only to material contribution to, or aggravation of, myocarditis where the person's myocarditis was suffered or contracted before or during (but did not arise out of) the person's relevant service.
10 Factors referring to an injury or disease covered by another Statement of Principles
In this Statement of Principles:
(1) if a factor referred to in section 8 applies in relation to a person; and
(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;
then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.
Schedule 1 - Dictionary
Note: See Section 5
1 Definitions
In this instrument:
MRCA means the Military Rehabilitation and Compensation Act 2004.
myocarditis—see subsection 6(2).
relevant service means:
(a) operational service under the VEA;
(b) peacekeeping service under the VEA;
(c) hazardous service under the VEA;
(d) British nuclear test defence service under the VEA;
(e) warlike service under the MRCA; or
(f) non-warlike service under the MRCA.
Note: MRCA and VEA are defined in the Schedule 1 - Dictionary.
terminal event means the proximate or ultimate cause of death and includes the following: